40372-03-0

Basic information

• Product Name: ribavirin 2',3',5'-triacetate
• Synonyms: ribavirin 2',3',5'-triacetate
• CAS NO: 40372-03-0
• Molecular Formula: C14H18N4O8
• Molecular Weight: 370.31472
• Mol File: 40372-03-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 555.6°Cat760mmHg
• Flash Point: 289.8°C
• Appearance: /
• Density: 1.6g/cm³
• Vapor Pressure: 2.19E-12mmHg at 25°C
• Refractive Index: 1.633
• PKA: 14.59±0.50(Predicted)
• CAS DataBase Reference: ribavirin 2',3',5'-triacetate(CAS DataBase Reference)
• NIST Chemistry Reference: ribavirin 2',3',5'-triacetate(40372-03-0)
• EPA Substance Registry System: ribavirin 2',3',5'-triacetate(40372-03-0)

Safety Data

• Hazardous Substances Data: 40372-03-0(Hazardous Substances Data)

Usage

Uses

Protected Ribavirin (R414475), a purine nucleoside analog; inhibits inosine monophosphate dehydrogenase (IMPDH). Used as an antiviral agent.This compound is suitable for pyruvate dehydrogenase (PDH) related research.

InChI:InChI=1/C14H18N4O8/c1-6(19)23-4-9-10(24-7(2)20)11(25-8(3)21)14(26-9)18-5-16-13(17-18)12(15)22/h5,9-11,14H,4H2,1-3H3,(H2,15,22)/t9-,10-,11-,14-/m1/s1

Upstream product

• 108-24-7 acetic anhydride 
• 36791-04-5 ribavirin 

Downstream Products

• 58151-87-4 5'-O-acetylribavirin 
• 120362-26-7 Ethyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate 
• 40372-00-7 ribamidine hydrochloride 
• 120362-25-6 methyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate 

Relevant articles and documents

Oligomer conjugates of heteropentacyclic nucleosides

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride)

Methyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate (4) and ethyl 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboximidate (6) were synthesized and tested for antitumor and antiviral activity. A new facile synthesis of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (5), starting with imidate 4, was also developed. The imidates 4 and 6 differed greatly in solubility and dosing requirements. Even so, both compounds exhibited significant activity in vivo against murine leukemia L1210. Nontoxic dosing with 4 also significantly diminished Friend leukemia induced splenomegaly. In contrast, neither imidate was active in vitro.